| In vitro simulation of thrombolysis inhibition. | |
| | |
MedLine Citation:
|
PMID: 18160584 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Hyperfibrinolysis is a serious clinical complication. The inhibitory concentrations 50% of antifibrinolytics were analyzed in the microtiter plate clot lysis assay, using 50 microL of plasma clots, 10 microL of antifibrinolytic drug, 10 microL of 354 IU/mL (final) urokinase, 4.46 microg/mL (final) tissue-type plasminogen activator or 0.6 mg/mL plasmin, and 50 microL of pooled normal plasma as clot supernatant. The inhibitory concentrations 50% of lysine against urokinase or tissue-type plasminogen activator is 2.0 or 4.2 mM, against epsilon-amino-caproic acid 0.7 or 1.5 mM, against tranexamic acid 0.03 or 0.17 mM, respectively. The inhibitory concentrations 50% of lysine, epsilon-amino-caproic acid, or tranexamic acid against plasmin is 7.4, 0.4, or 0.04 mM. The inhibitory concentrations 50% of aprotinin against urokinase or tissue-type plasminogen activator is about 60 KIU/mL, against plasmin 19 KIU/mL. Lysine might be a new antifibrinolytic drug with a clinically interesting rapid pharmacokinetic. This data help correct dosing of antifibrinolytics to patients with hyperfibrinolysis. |
| | |
Authors:
|
Thomas W Stief |
Related Documents
:
|
14595654 - Valproic acid increases smn levels in spinal muscular atrophy patient cells. 16364054 - In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteo... 20479544 - Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandron... 22095764 - The role of rna in mammalian prion protein conversion. 14751684 - Effect of iron limitation on the growth and cytotoxin production of salmonella cholerae... 9474814 - Identification of selenocysteine and selenomethionine in protein hydrolysates by high-p... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2007-12-26 |
Journal Detail:
|
Title: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis Volume: 14 ISSN: 1076-0296 ISO Abbreviation: Clin. Appl. Thromb. Hemost. Publication Date: 2008 Apr |
Date Detail:
|
Created Date: 2008-03-28 Completed Date: 2008-05-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9508125 Medline TA: Clin Appl Thromb Hemost Country: United States |
Other Details:
|
Languages: eng Pagination: 234-7 Citation Subset: IM |
Affiliation:
|
Department of Clinical Chemistry, University Hospital, Marburg, Germany. thstief@med.uni |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
6-Aminocaproic Acid
/
pharmacology* Antifibrinolytic Agents / pharmacology* Aprotinin / pharmacology* Humans Lysine / pharmacology* Tranexamic Acid / pharmacology* |
| Chemical | |
Reg. No./Substance:
|
0/Antifibrinolytic Agents; 1197-18-8/Tranexamic Acid; 56-87-1/Lysine; 60-32-2/6-Aminocaproic Acid; 9087-70-1/Aprotinin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Soluble fibrin inhibits lymphocyte adherence and cytotoxicity against tumor cells: implications for ...
Next Document: In vitro simulation of extremely activated thrombolysis.